284492-24-6 Usage
Description
3-TERT-BUTOXYCARBONYLAMINO-3-FURAN-3-YL-PROPIONIC ACID is a chemical compound characterized by a furan ring attached to a propionic acid backbone and a tert-butoxycarbonylamino group. It is recognized for its potential anti-inflammatory and analgesic properties, as well as its utility as a building block in the synthesis of pharmaceuticals and organic compounds. Its stability and mild removal conditions also make it a valuable protecting group in peptide synthesis.
Uses
Used in Pharmaceutical Industry:
3-TERT-BUTOXYCARBONYLAMINO-3-FURAN-3-YL-PROPIONIC ACID is used as a building block for the synthesis of various pharmaceuticals due to its potential anti-inflammatory and analgesic properties, contributing to the development of new drugs for pain relief and inflammation management.
Used in Organic Chemistry Research:
3-TERT-BUTOXYCARBONYLAMINO-3-FURAN-3-YL-PROPIONIC ACID is used as a key component in the synthesis of organic compounds, facilitating the creation of diverse chemical structures for research and potential applications.
Used in Peptide Synthesis:
3-TERT-BUTOXYCARBONYLAMINO-3-FURAN-3-YL-PROPIONIC ACID is used as a protecting group in peptide synthesis, providing stability during the synthesis process and allowing for mild conditions to remove the group, which is crucial for maintaining the integrity of the peptide being synthesized.
Check Digit Verification of cas no
The CAS Registry Mumber 284492-24-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,4,4,9 and 2 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 284492-24:
(8*2)+(7*8)+(6*4)+(5*4)+(4*9)+(3*2)+(2*2)+(1*4)=166
166 % 10 = 6
So 284492-24-6 is a valid CAS Registry Number.
284492-24-6Relevant articles and documents
COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
-
Page/Page column 89; 90, (2014/01/09)
The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
